Drug Trial Radar · NCT00514514
Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen
Last checked: Nov 20, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
802
Actual
Start
Jul 2007
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 10, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare renal function of immunosuppressive regimens with different relevance of the calcineurin inhibitor (CNI) cyclosporine: standard dose CNI, low dose CNI, CNI free in de novo kidney transplant patients after 12 months of therapy.
Conditions
- Kidney Transplantation
Interventions
EverolimusDrug
Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
MyforticDrug
1 tablet containing 180 mg or 360 mg Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)
Sandimmun OptoralDrug
1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
Simulect®Drug
Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
Primary outcomes
What the sponsor says the trial is designed to measure.
- GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard RegimenTime frame: From randomization at BL2 (Month 3) to Month 12 post-transplant
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Frankfurt am Main, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hannover Muenden, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Kaiserslautern, Germany
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Regensburg, Germany
Novartis Investigative Site
Bern, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.